Moderna (MRNA) Set to Post Quarterly Earnings on Friday

Key Points

• Moderna is expected to report Q3 2026 results before market open on Nov. 6. Analysts forecast a loss of $1.11 per share and revenue of approximately $891.3 million.
• The company remains unprofitable, with analysts expecting full-year EPS of negative $6.11, while recent insider selling and lowered earnings estimates highlight ongoing profitability and valuation concerns.
• Investor optimism is focused on Moderna’s personalized cancer-vaccine program, though the stock carries a consensus “Hold” rating and a $107.10 price target despite recent gains.

Moderna (NASDAQ:MRNA - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($1.11) per share and revenue of $891.34 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. Moderna's quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($2.13) EPS. On average, analysts expect Moderna to post ($6.11) EPS for the current fiscal year and ($4.50) EPS for the next fiscal year.

Moderna Trading Up 4.0%

Shares of MRNA stock opened at $222.76 on Friday. Moderna has a 52 week low of $22.28 and a 52 week high of $254.48. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The stock's fifty day moving average is $180.72 and its 200-day moving average is $85.58.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MRNA shares. Sanford C. Bernstein reiterated a "market perform" rating on shares of Moderna in a research note on Friday, September 25th. Morgan Stanley upped their target price on shares of Moderna from $89.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, October 7th. Jefferies Financial Group reiterated a "hold" rating and issued a $150.00 target price (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Bradesco Corretora upgraded Moderna to an "outperform" rating in a report on Friday, August 28th. Finally, TD Cowen reiterated a "buy" rating on shares of Moderna in a report on Wednesday, October 21st. Six research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus price target of $107.10.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer vaccine candidate recently produced positive clinical-trial data, renewing investor optimism about a potentially significant oncology business. The upcoming Nov. 6 event or update could provide another near-term catalyst. Will Moderna Soar on Nov. 6?
• Positive Sentiment: CEO Stéphane Bancel defended the melanoma-vaccine results, saying the data should improve over time and that Moderna’s technology may be difficult for competitors to replicate. He also expressed confidence that the platform could work in cancers beyond melanoma. Moderna CEO Cancer Vaccine Commentary
• Neutral Sentiment: Moderna’s ESMO presentation highlighted the science behind its oncology pipeline, but investors now want evidence that the program can translate into commercial revenue and improve the company’s financial outlook. Moderna ESMO Presentation
• Neutral Sentiment: Heavy investor searches for Moderna indicate elevated market interest, but the coverage does not identify a new fundamental development by itself. Investors Heavily Search Moderna
• Negative Sentiment: William Blair lowered Moderna to Market Perform from Outperform, citing valuation concerns after the stock’s strong oncology-driven advance. The downgrade suggests much of the cancer-vaccine optimism may already be reflected in the shares. William Blair Downgrades Moderna
• Negative Sentiment: An analyst lowered the FY2028 EPS estimate, reinforcing concerns about Moderna’s path to profitability and the premium valuation investors are assigning to its future pipeline. Comparisons with GSK emphasize that Moderna offers greater oncology upside but less income and currently higher execution risk. GSK vs. Moderna Growth Comparison

Insider Buying and Selling at Moderna

In related news, President Stephen Hoge sold 40,294 shares of the company's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the transaction, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the firm's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 197,251 shares of company stock valued at $33,875,904 in the last three months. 10.80% of the stock is currently owned by company insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.